Literature DB >> 8804362

Dermal fibroblast culture as a model system for studies of fibrillin assembly and pathogenetic mechanisms: defects in distinct groups of individuals with Marfan's syndrome.

T Brenn1, T Aoyama, U Francke, H Furthmayr.   

Abstract

Most patients with Marfan's syndrome (> 95%) and 75% of patients with uncertain diagnosis can be classified into four groups (Aoyama et al, 1994, 1995) based on abnormal patterns of synthesis, intracellular transport, and/or matrix deposition of fibrillin-1 in fibroblast cultures. Herein we report a systematic study of fibrillin assembly in normal and Marfan's syndrome fibroblasts and correlations between pulse-chase, immunofluorescence, and immunoelectron microscopic data. Normal control fibroblasts were grown at confluent conditions from 2 to 10 days before passage and then maintained at hyperconfluent cell densities for an additional period of 1 to 6 days before assaying. Maximum deposition in the extracellular matrix of pulse-labeled fibrillin required at least 6 days of confluent and 4 to 5 days of hyperconfluent culture. This result is explained by immunofluorescence studies with fibrillin-1-specific antibodies, because 1 day after seeding cells at hyperconfluency, patches of regular immunostained structures were already present. Within these patches, fluorescence intensity and fibrillar material increased over 3 to 4 days, and after only 5 days, fibrillar networks extended throughout the culture. We propose that fibrillin-containing microfibrillar material is passaged together with the cells, newly synthesized fibrillin molecules are deposited onto preexisting microfibrillar assemblies, and several additional days of culture at high cell density are necessary for the cells to construct a sufficient microfibrillar network binding and detection of pulse-labeled fibrillin molecules in insoluble form during a 20-hour chase period. This fraction is decreased to a varying extent in fibroblast cultures of four biosynthetically distinct groups of Marfan's syndrome patients, but only Groups II and IV clearly showed reduction in immunostainable microfibrils. In long-term cultures, immunoelectron microscopy of the extracellular matrix with fibrillin antibodies also detected differences among these groups and in comparison to normal controls with respect to the arrangement of fibrillin-containing microfibrils, thickness of microfibrillar bundles, and the presence of amorphous material. The data support the idea of different pathogenetic mechanisms for each biosynthetically defined group of Marfan's syndrome, which depends on the nature of fibrillin-1 mutations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804362

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  Human microvascular lymphatic and blood endothelial cells produce fibrillin: deposition patterns and quantitative analysis.

Authors:  Antonella Rossi; Erica Gabbrielli; Marilisa Villano; Mario Messina; Francesco Ferrara; Elisabetta Weber
Journal:  J Anat       Date:  2010-10-11       Impact factor: 2.610

2.  Immunohistochemical analysis of collagen expression in uterine leiomyomata during the menstrual cycle.

Authors:  Masaaki Iwahashi; Yasuteru Muragaki; Makoto Ikoma; Yasushi Mabuchi; Aya Kobayashi; Yuuko Tanizaki; Kazuhiko Ino
Journal:  Exp Ther Med       Date:  2011-01-05       Impact factor: 2.447

Review 3.  The molecular genetics of Marfan syndrome and related disorders.

Authors:  P N Robinson; E Arteaga-Solis; C Baldock; G Collod-Béroud; P Booms; A De Paepe; H C Dietz; G Guo; P A Handford; D P Judge; C M Kielty; B Loeys; D M Milewicz; A Ney; F Ramirez; D P Reinhardt; K Tiedemann; P Whiteman; M Godfrey
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

4.  Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes.

Authors:  I Schrijver; W Liu; T Brenn; H Furthmayr; U Francke
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

5.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome.

Authors:  Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes.

Authors:  Iris Schrijver; Wanguo Liu; Raanan Odom; Thomas Brenn; Peter Oefner; Heinz Furthmayr; Uta Francke
Journal:  Am J Hum Genet       Date:  2002-06-14       Impact factor: 11.025

7.  A Marfan syndrome gene expression phenotype in cultured skin fibroblasts.

Authors:  Zizhen Yao; Jochen C Jaeger; Walter L Ruzzo; Cecile Z Morale; Mary Emond; Uta Francke; Dianna M Milewicz; Stephen M Schwartz; Eileen R Mulvihill
Journal:  BMC Genomics       Date:  2007-09-12       Impact factor: 3.969

8.  Multi-exon deletions of the FBN1 gene in Marfan syndrome.

Authors:  W Liu; I Schrijver; T Brenn; H Furthmayr; U Francke
Journal:  BMC Med Genet       Date:  2001-10-24       Impact factor: 2.103

9.  Genetic and molecular mechanism for distinct clinical phenotypes conveyed by allelic truncating mutations implicated in FBN1.

Authors:  Mao Lin; Zhenlei Liu; Gang Liu; Sen Zhao; Chao Li; Weisheng Chen; Zeynep Coban Akdemir; Jiachen Lin; Xiaofei Song; Shengru Wang; Qiming Xu; Yanxue Zhao; Lianlei Wang; Yuanqiang Zhang; Zihui Yan; Sen Liu; Jiaqi Liu; Yixin Chen; Yuzhi Zuo; Xu Yang; Tianshu Sun; Xin-Zhuang Yang; Yuchen Niu; Xiaoxin Li; Wesley You; Bintao Qiu; Chen Ding; Pengfei Liu; Shuyang Zhang; Claudia M B Carvalho; Jennifer E Posey; Guixing Qiu; James R Lupski; Zhihong Wu; Jianguo Zhang; Nan Wu
Journal:  Mol Genet Genomic Med       Date:  2019-11-27       Impact factor: 2.183

10.  Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide.

Authors:  Marilisa Villano; Annalisa Borghini; Mirko Manetti; Erica Gabbrielli; Antonella Rossi; Piersante Sestini; Anna Milia; Francesca Nacci; Serena Guiducci; Marco Matucci-Cerinic; Lidia Ibba-Manneschi; Elisabetta Weber
Journal:  Arthritis Res Ther       Date:  2013-08-20       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.